MT-2

Mechanism

MT-2, or Melanotan 2, is a synthetic peptide that stimulates melanin production in the skin, producing a tan without significant UV exposure. Beyond tanning, it also has effects on sexual arousal, appetite suppression, and fat metabolism through its action on multiple melanocortin receptors. It is widely used but carries a higher side effect profile than more selective melanocortin peptides, including nausea, facial flushing, and the development of new moles or darkening of existing ones.

Effects

## Integumentary System — Melanogenesis [Tier 1 — Extensive Human Data (Off-Label)] Melanotan II (MT-2) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds non-selectively to melanocortin receptors MC1R through MC5R, with highest affinity for MC1R (melanogenesis), MC3R, MC4R (sexual function, appetite), and MC5R (exocrine function). Activation of MC1R on melanocytes upregulates tyrosinase via cAMP/PKA/MITF signaling, increasing eumelanin synthesis. This produces visible skin darkening (tanning) without UV exposure, though UV exposure dramatically potentiates the effect. Tanning typically begins within 5-7 days of initial dosing and becomes pronounced by 2-3 weeks. The pigmentation is NOT cosmetically uniform — it preferentially darkens areas with higher melanocyte density: face, arms, genital region, and existing moles/nevi. Mole darkening is essentially universal and is a significant safety concern (see below). ## Reproductive/Sexual System [Tier 1 — Human Data] MT-2 produces reliable pro-sexual effects via MC3R and MC4R activation in the hypothalamus and spinal cord. Effects include increased libido, spontaneous erections in men, and increased genital arousal in women. These effects were the basis for the development of PT-141 (bremelanotide, a metabolite/derivative of MT-2). Sexual side effects occur in the vast majority of users at tanning doses — they are essentially inseparable from the tanning effect. ## Gastrointestinal System [Tier 1 — Human Data] Nausea is the most common acute side effect, occurring in 50-85% of users during the initial loading phase. The nausea is mediated by MC4R activation in the area postrema (chemoreceptor trigger zone) and brainstem vagal circuits. It is typically most severe during the first 3-5 injections and tends to diminish with continued use (tachyphylaxis). Appetite suppression is common and mediated by MC4R in the hypothalamus — the same pathway targeted by setmelanotide (Imcivree) for obesity. ## Cardiovascular System [Tier 2 — Human Data] MT-2 causes facial flushing in 30-50% of users (vasodilation via MC1R on vascular endothelium). Transient increases in blood pressure have been reported. Heart rate changes are minimal at standard doses. ## Dermatologic Safety Concerns [Tier 2 — Case Reports and Surveillance Data] **Mole darkening and new nevi:** Virtually all users report darkening of existing moles and freckling. New nevi can appear. This makes melanoma surveillance more difficult because the classic ABCDE signs (asymmetry, border irregularity, color change, diameter increase) are confounded by the drug itself. **Melanoma concern:** Multiple case reports of melanoma diagnosed in MT-2 users. The causal relationship is debated — MC1R activation theoretically could either protect (by increasing eumelanin, which is photoprotective) or harm (by stimulating melanocyte proliferation in those with pre-existing dysplastic nevi or genetic predisposition). The WHO, TGA (Australia), and multiple dermatology organizations have issued warnings.

Practitioner Guide

## Real-World Tanning Protocol (What Users Actually Do) ### The Loading Phase The standard community protocol is a "loading" phase followed by maintenance: - **Loading dose:** 250-500 mcg SC daily for 2-4 weeks while getting UV exposure (sun or tanning bed, 15-20 minutes 3x/week). Some users start at 100 mcg to assess tolerance. - **Injection timing:** Most users inject in the evening to sleep through the nausea. Alternatively, inject 30-60 minutes before UV exposure for maximum melanogenesis synergy. - **Injection site:** SC injection in abdominal fat. Rotation of sites recommended. - **Expected timeline:** Faint color change by day 5-7. Noticeable tan by day 10-14. Full "desired tan" by day 20-30 for most skin types. Fitzpatrick Type I-II (very fair) users need longer loading and more UV exposure. ### Maintenance Phase - **Dose:** 250-500 mcg once or twice per week with continued but reduced UV exposure. - **Duration:** Users typically maintain for the duration they want the tan (seasonal or year-round). Tanning fades gradually (over 1-3 months) after discontinuation. ### Managing Nausea — The #1 Side Effect Nausea is the main reason people abandon MT-2. Practical management strategies: 1. **Start low:** Begin at 100-150 mcg and titrate up over 5-7 days. The nausea response diminishes with repeated exposure. 2. **Evening dosing:** Inject before bed. Most users sleep through the worst nausea (peaks at 30-90 minutes post-injection). 3. **Empty stomach vs. light meal:** Opinions vary. Most experienced users prefer empty stomach (less to vomit) with injection at bedtime. 4. **Anti-emetics:** Ginger (1g) 30 minutes pre-injection, or ondansetron (Zofran) 4mg for severe cases. Diphenhydramine (Benadryl) 25mg also helps and promotes sleep. 5. **Slow injection:** Inject slowly over 30-60 seconds rather than bolus. 6. **Tachyphylaxis is real:** Nausea almost always diminishes by injection 5-7. Encourage patients to push through the first week. ### Sexual Side Effects — The "Feature" That Is Also a Bug - Spontaneous erections are common in men, especially during loading phase. This is dose-dependent and can be socially awkward. - Increased libido occurs in both men and women. Some users specifically want this effect (MT-2 is cheaper than PT-141). - Sexual effects can be managed by lowering dose, but at doses that produce good tanning, some sexual effect is almost inevitable. ### Mole Darkening — The Critical Safety Issue **This is non-negotiable:** ALL patients using MT-2 must: 1. **Baseline full-body skin examination** by a dermatologist with dermoscopy, ideally with total body photography (mole mapping) BEFORE starting MT-2. 2. **Follow-up skin examination** every 3-6 months while using MT-2. 3. **Self-monitoring:** Instruct patients to photograph all moles monthly and report any that change in size, shape, color, or symmetry BEYOND the expected uniform darkening. 4. **Absolute contraindications:** History of melanoma, family history of melanoma in first-degree relative, atypical mole syndrome (dysplastic nevus syndrome), >50 nevi, or any mole with current ABCDE warning signs. ### Why MT-2 Remains Popular Despite Safety Concerns 1. **It works dramatically** — produces a deep, natural-looking tan that lasts, even in very fair-skinned individuals. 2. **Reduces UV exposure needed** — paradoxically, some users argue it is safer than conventional tanning because far less UV is needed. 3. **Sexual side effects are desired** by many users (it is cheaper and more accessible than PT-141/Vyleesi). 4. **Appetite suppression** is a welcome side effect for many. 5. **Widely available** from peptide research chemical suppliers despite regulatory warnings. 6. **Cost:** Approximately $15-30 per 10mg vial (enough for 20-40 doses at 250-500 mcg), making it extremely cost-effective. ### What Practitioners Should Know - MT-2 is not FDA-approved for any indication. It is explicitly banned by the TGA in Australia and the FDA has issued import alerts. - Users are self-administering regardless of practitioner guidance. Harm reduction is the practical approach. - The risk-benefit conversation should center on: melanoma screening compliance, skin type (higher risk in Type I-II), personal/family melanoma history, and whether the sexual effects are desired or problematic. - Drug interactions: Use caution with PDE5 inhibitors (additive BP effects), antihypertensives (additive hypotension), and drugs affecting melanocyte function.

Dosing Protocols

Contraindications & Cautions

• hard stop — Uncontrolled hypertension
  Melanotan II acts on melanocortin receptors and can cause blood pressure fluctuations. Patients with uncontrolled hypertension face elevated cardiovascular risk.
  Action: Do not use in patients with uncontrolled hypertension. Blood pressure must be adequately controlled before considering use.
• hard stop — History of melanoma
  MT-2 is a potent, non-selective melanocortin receptor agonist that strongly stimulates melanocyte activity. This mechanism carries significant risk of promoting melanoma development, growth, or recurrence. MT-2 has been associated with changes in existing moles and new nevi formation.
  Action: Do not use in patients with active melanoma, history of melanoma, or significant melanoma risk factors (numerous atypical nevi, family history, fair skin with extensive UV damage). Monitor all moles closely if use has occurred.
• hard stop — Pregnancy
  No human safety data. Non-selective melanocortin activation poses unknown developmental risks. MT-2 affects multiple hormonal pathways.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Breastfeeding
  No data on excretion in breast milk. Non-selective melanocortin activation poses unknown risks to nursing infant.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Non-selective melanocortin activation poses unknown risks to developing physiology.
  Action: Do not provide peptide protocols to individuals under 18.
• requires physician — Cardiovascular disease
  MT-2 may affect blood pressure and heart rate via melanocortin receptor activation. Patients with cardiovascular disease face increased risk.
  Action: Requires cardiovascular evaluation before initiation. Monitor blood pressure.
• requires physician — PDE5 inhibitors
  Concurrent use of MT-2 with PDE5 inhibitors may cause additive blood pressure changes and unpredictable cardiovascular effects.
  Action: Avoid concurrent use. If combined, requires physician supervision and blood pressure monitoring.

Research Summary

## Tier 1 — Strong Clinical Evidence - MT-2 reliably induces melanogenesis (skin darkening) in humans across multiple controlled studies (Dorr et al., Life Sciences 1996; Hadley et al., multiple publications) - MC1R-mediated tanning mechanism is well-established with strong molecular biology support - Pro-sexual effects (erections, increased libido) confirmed in multiple Phase I/II studies — this led to development of PT-141/bremelanotide - Nausea, facial flushing, and appetite suppression consistently reported in 50-85% of subjects ## Tier 2 — Moderate Evidence - Safety concern: multiple case reports of melanoma in MT-2 users (Hjuler et al., Dermatology 2015; Reid & Naraghi, BMJ Case Reports 2012; Guichard et al., Dermatology 2014). Causality not established but biological plausibility exists via MC1R-mediated melanocyte proliferation. - WHO, TGA, and FDA warnings against use based on unregulated manufacturing, no long-term safety data, and melanoma concern - Darkening of existing nevi is universal at effective tanning doses — confirmed in clinical studies and large user surveys - Appetite suppression consistent with MC4R activation (same pathway as FDA-approved setmelanotide) ## Tier 3 — Preclinical/Theoretical - Potential photoprotective effect: increased eumelanin may reduce UV-induced DNA damage (preclinical data support this; clinical relevance unknown given the concurrent melanocyte proliferation concern) - Long-term effects of chronic MC1R/MC4R activation unknown — no multi-year safety studies exist - Possible adrenal effects via MC2R/MC5R cross-reactivity — not studied in humans - Immunomodulatory effects via MC3R/MC5R on immune cells — theoretical